AngioDynamics Touts Debt-Free Turnaround, Auryon Gains, and NanoKnife Launch

CEO highlights growth drivers in MedTech segment and clinical plans for key platforms at Needham Healthcare Conference.

Apr. 15, 2026 at 1:03am

Got story updates? Submit your updates here. ›

A close-up photograph of a sleek, metallic medical device component, such as a laser tip or catheter hub, arranged elegantly on a clean, monochromatic background to symbolize the precision and innovation of AngioDynamics' MedTech products.AngioDynamics' innovative medical devices, like the Auryon laser atherectomy platform, are driving the company's strategic transformation and growth.Latham Today

AngioDynamics CEO Jim Clemmer used a presentation at the Needham Healthcare Conference to outline the company's multi-year transformation, including three divestitures, balance sheet strengthening, and a focus on its MedTech segment as the future growth engine. Clemmer highlighted the Auryon laser atherectomy platform in peripheral arterial disease, the AngioVac and AlphaVac platforms in the pulmonary embolism market, and the NanoKnife system for prostate cancer treatment.

Why it matters

AngioDynamics' strategic reset and debt-free balance sheet position the company to invest in and expand its core MedTech platforms, which now account for nearly half of total revenue and are growing at a 25% compound annual rate. The company's focus on innovative devices in high-growth areas like peripheral artery disease, pulmonary embolism, and prostate cancer treatment could drive further market share gains.

The details

Clemmer said AngioDynamics has moved from the sixth entrant in the Auryon laser atherectomy category to the number-three share position and believes it can continue taking share. The company is also working to expand Auryon's use internationally and evaluating a potential move into the coronary arterial market. In venous disease, Clemmer highlighted the AngioVac and AlphaVac platforms for pulmonary embolism treatment, noting that AlphaVac's APEX trial showed improved performance versus prior benchmarks. On the oncology side, Clemmer pointed to the NanoKnife system's FDA clearance in 2024 for intermediate-risk prostate cancer, describing a nearly $1 billion U.S. TAM and over $2 billion global TAM for this treatment approach.

  • AngioDynamics began a strategic reset roughly five to six years ago.
  • The company launched the Auryon laser atherectomy platform commercially in September 2020.
  • NanoKnife received FDA clearance in December 2024 and obtained a CPT I code effective January 1, 2025.

The players

Jim Clemmer

CEO of AngioDynamics.

Auryon

AngioDynamics' laser atherectomy platform for peripheral arterial disease.

AngioVac

AngioDynamics' foundational platform for extracting clot or vegetation during complex procedures.

AlphaVac

AngioDynamics' purpose-built pulmonary embolism thrombectomy device.

NanoKnife

AngioDynamics' system for focal therapy in intermediate-risk prostate cancer.

Got photos? Submit your photos here. ›

What they’re saying

“Today, we're sitting here as a company with no debt on our books, significant cash position, a revolver if needed, but the ability to do what we want to do on our terms.”

— Jim Clemmer, CEO

“It's about 50/50, adding that the mix reflects adoption of Auryon's ability to treat hard calcification below the knee as well as above it.”

— Jim Clemmer, CEO

“We've seen some change and disruption, but have remained focused on expanding our own commercial and clinical footprint.”

— Jim Clemmer, CEO

What’s next

AngioDynamics plans to run a study in Europe to help energize the pulmonary embolism market there and is evaluating the regulatory pathway and study design for potentially using NanoKnife to treat benign prostatic hyperplasia (BPH).

The takeaway

AngioDynamics' strategic transformation, debt-free balance sheet, and focus on high-growth MedTech platforms like Auryon, AngioVac/AlphaVac, and NanoKnife position the company to capitalize on opportunities in peripheral artery disease, pulmonary embolism, and prostate cancer treatment.